The American College of Rheumatology (ACR) has updated its health policy statements for 2018, and biosimilars featured heavily in the organization’s concerns for the year ahead.
The American College of Rheumatology (ACR) has updated its health policy statements for 2018, and biosimilars featured heavily in the organization’s concerns for the year ahead.
ACR underscored its support of biosimilars, which it recently voiced in detail in the group’s white paper on biosimilars, saying that the organization is “committed to advocating for a smooth transition to an era of less expensive biologics that provide safe, effective treatments that are accessible to more people.” ACR says that it remains opposed to forced switching of patients’ therapy, and also opposes legislation or regulation that permits a pharmacist to substitute a biologic or biosimilar for another (unless the pharmacist is acting in accordance with a collaborative practice agreement with the prescriber). In jurisdictions where such legislation exists, providers must retain the right to demand that a prescription be dispensed as written, says ACR.
The organization also calls for biologic medicine administration to be reimbursed at the complex rate under Medicare Part B, saying that, in recent years, a growing number of contractors have stopped reimbursing at this rate without consulting with physicians, as required by law. “Reduced reimbursement and coverage for medically necessary care and treatment will force doctors to reduce services they offer. Therefore, without proper coverage of these treatments, access to therapy is threatened.”
ACR says that specialty tiers for biologic medicines that require high patient cost sharing also pose a barrier to care, and that federal, state, and local legislation should restrict such tiering by commercial insurance carriers. Other legislative tools to reduce out-of-pocket costs, such as caps on total annual out-of-pocket spending, should be explored.
The organization also expresses concerns about patient assistance programs for high-cost drugs like biologics and biosimilars; while having the benefit of providing access to critical treatments for patients who otherwise would be unable to afford their medicines, patient assistance programs insulate patients from drug costs and may distort demand for lower-cost therapies, such as biosimilars. “As such, these programs may be best paired with other measures to reduce drug list prices, and are suboptimal compared to basic cost coverage strategies,” says the ACR.
However, as long as Medicare does not cover the cost of crucial treatments, the ACR says that it will support increased access to these programs for Medicare Part D beneficiaries, and will support legislation that would allow Part B and Part D beneficiaries to receive financial copay assistance as part of these programs. It also opposes insurance restrictions preventing the application of funds from assistance programs to patients’ deductibles and out-of-pocket minimums.
Finally, in order to address the high cost of medicines, ACR supports legislation that would allow Medicare to negotiate directly with pharmaceutical companies to achieve more affordable pricing of drugs, and says that there must be increased transparency in how drug companies, pharmacy benefit managers, and payers determine the costs of medicines.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.